Therefore, STING agonists have potential as a novel therapeutic option for treatment of genital herpes, due to their small molecular size and targeted type I IFN-biased response, which in addition induces type III IFN, autophagy, programmed death pathways, and low levels of inflammatory cytokines. The gene discussed is STING1; the disease is genital herpes.